AAN 2025 | QoL outcomes from the Phase III trial of subcutaneous carbidopa-levodopa infusion for PD
Harini Sarva, MD, Weill Cornell Medicine, New York, NY, comments on quality of life (QoL) outcomes from the Phase III (NCT04006210) randomized trial of the subcutaneous carbidopa-levodopa infusion for Parkinson’s disease (PD). She notes a nearly two-hour improvement in on-time motor function and better quality of life scores, including body perception, activities of daily living, and mobility, compared with oral medications alone. This interview took place at the 77th American Academy of Neurology (AAN) Annual Meeting in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so the Phase III randomized trial for the subcutaneous carba-levo infusion were positive. There was almost nearly two-hour improvement in on time in terms of the motor function. And as part of that study, there was also quality of life assessments that were done through the PDQ-39 and other quality assessments. And for the patients who were part of the infusion versus those who didn’t get the infusion, they just got the oral medications, the quality of life was better, not only in terms of the overall score, but also on multiple subdomains, including their body perception, their activities of daily living, just mobility...
Yeah, so the Phase III randomized trial for the subcutaneous carba-levo infusion were positive. There was almost nearly two-hour improvement in on time in terms of the motor function. And as part of that study, there was also quality of life assessments that were done through the PDQ-39 and other quality assessments. And for the patients who were part of the infusion versus those who didn’t get the infusion, they just got the oral medications, the quality of life was better, not only in terms of the overall score, but also on multiple subdomains, including their body perception, their activities of daily living, just mobility. So in many facets, it was better, statistically significantly better than the oral.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
I received research support for my work on clinical trials from Biogen, Meira GTX, Sun Pharma, Bukwang, Genentech, Prevail, BlueRock, Neuroderm, UCB, Cerevance and Novo Nordisk.
